Market Newsdesk

Gaithersburg, MD, March 29, 2021 (GLOBE NEWSWIRE) — Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS) reported financial results for the fiscal 2021 first quarter ended January 31, 2021. In conjunction with this release, the Company is also providing additional details on business developments subsequent to the quarter’s end.

For fiscal Q1 2021, management is noting the following items of importance:

• Revenue decreased 44% on a year-over-year basis to $3.5 million during Q1 2021 compared to $6.2 million during fiscal Q1 2020, due in part to a planned product line repositioning that is expected to contribute higher margin revenue beginning in Q2 2021;
• Gross profit margin was 17.1% for fiscal Q1 2021, 338 basis points lower than the 20.5% generated during fiscal Q1 2020;
• Operating expenses of $0.7 million were 73% lower than fiscal Q1 2020 operating expenses of $2.6 million, primarily due to the completion of the former CEO’s stock-based compensation program and expense rationalization measures across nearly all business categories;
• Operating loss of $0.1 million was 92% lower than the $1.4 million reported in fiscal Q1 2020;
• Net loss from continuing operations was $0.4 million, an 80% improvement over the $2.3 million reported in the prior year period, with non-cash expenses decreasing $0.6 million year-over-year; and
• Gross convertible notes payable decreased 35% to $273,000 in Q1 2021 compared to $423,000 in the prior quarter, Q4 2020.

“This quarter showed our commitment to become a profitable company,” explained Verus CEO Andy Dhruv. “That process begins with expense rationalization. While decoupling from our most capital-intensive business units, we also have been aggressively optimizing expenses in nearly every operating category. We now have a smaller footprint, with lower operating costs across our organization, from office space to legal expenses, giving us a fresh start while we implement our new product line strategy. This plan will stress quick turnaround sales of high margin, high demand products under our own in-house developed brands, which do not require royalty payments. In that regard, we are also actively working to rapidly transition a larger portion of our sales into the CBD category, where our margins are three to five times higher than our traditional food business. We still have some work to do to accelerate this strategy, but we have completed the first steps to position ourselves for future growth. Our singular focus is to become profitable as soon as possible.”

Operational Update

With the filing of the fiscal Q1 2021 Form 10-Q, Verus is now compliant in its filings. As a result, management is able to actively resume previously announced M&A discussions. In conjunction with these corporate actions, Verus plans to significantly reduce its authorized share count when the structure of the M&A is better defined. Management cannot be certain of the timing or the outcome of these active M&A discussions, which involve companies of equal or greater size than Verus’ current operations. The Company will provide a more complete corporate update in the near future, with additional details on its strategic plan for the remainder of 2021.

About Verus International

Verus is an emerging multi-line consumer packaged goods (CPG) company developing branded product lines in the U.S. and on a global basis. The Company trades on the OTC market (OTC Pink: VRUS). Investors can find real-time quotes and market information for the Company on www.otcmarkets.com. Additional information is also available at the Company’s website, www.verusfoods.com, and via the official Twitter feed @Verus_Foods, and the Pachyderm Labs subsidiary Twitter feed @PachydermLabs.

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results could differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Contacts

Investor Contact:

MKR Group Inc.
Todd Kehrli or Mark Forney
[email protected]

The transaction reduces leverage, accelerates recurring fee income, and expands a key institutional partnership

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — WPT Industrial Real Estate Investment Trust (the “REIT”) (TSX: WIR.U; WIR.UN; OTCQX: WPTIF) announced today that it will contribute a portfolio of 13 U.S. distribution and logistics properties (the “Portfolio”) with a value of approximately $370 million into a newly established joint venture with the Investment Management Corporation of Ontario (the “Joint Venture”). 

All dollar amounts are stated in U.S. funds.

Completion of the Joint Venture advances the REIT’s previously announced capital recycling initiative, while reducing overall leverage and increasing liquidity. The REIT will retain a majority ownership interest in the Portfolio and continue to manage and operate the properties on behalf of the Joint Venture. The Joint Venture, which will hold stabilized, income producing properties, expands the REIT’s base of recurring third-party management fee income and includes future leasing and incentive fees.

“The formation of a new stabilized joint venture represents meaningful progress on our capital recycling initiative and underscores the REIT’s ability to attract and expand our relationships with strong institutional capital partners. The transaction strengthens our balance sheet, provides additional capacity to fund our growing development pipeline, and accelerates growth in our private capital management platform,” commented Scott Frederiksen, Chief Executive Officer of the REIT.

Key Highlights

• Generates approximately $255 million in sale and financing proceeds, which will be used by the REIT to pay down debt and fund future development and investment activity
• Decreases debt-to-assets by approximately 4% on a consolidated basis and approximately 2% on a proportionate share basis, resulting in liquidity of approximately $153 million
• Facilitates capital recycling out of select markets and large, single-tenant properties while maintaining existing operational scale
• Increases recurring third-party management fee revenue

Portfolio Overview

• Approximately 4,750,000 square feet of gross leaseable area (GLA)
• Average tenant size of 317,000 square feet
• 100% leased with a weighted average lease term of approximately 5.5 years
• Initial capitalization with debt-to-total-assets of 45%
• Portfolio contribution value slightly above current IFRS fair value

Additional property information regarding the Portfolio is set out below:

While the REIT’s contribution of the Portfolio to the Joint Venture was structured in a tax efficient manner, the REIT anticipates that the transaction will give rise to some taxable income for Canadian tax purposes. Such income may result in an increase in the taxable portion of the REIT’s regular distributions or be distributed to the REIT’s unitholders as a special distribution of cash or additional trust units of the REIT. Any such special distribution must be declared before December 31, 2021 and will be announced prior to the end of 2021.

About WPT Industrial Real Estate Investment Trust

WPT Industrial Real Estate Investment Trust is an unincorporated, open-ended real estate investment trust established pursuant to a declaration of trust under the laws of the Province of Ontario. The REIT acquires, develops, manages and owns distribution and logistics properties located in the United States. WPT Industrial, LP (the REIT’s operating subsidiary) indirectly owns or manages a portfolio of properties across 20 U.S. states consisting of approximately 37.2 million square feet of GLA and 109 properties. The REIT pays monthly cash distributions, currently at $0.0633 per Unit, or approximately $0.76 per Unit on an annualized basis, in US funds.

For more information, please contact:
Scott Frederiksen, Chief Executive Officer
WPT Industrial Real Estate Investment Trust
Tel: (612) 800-8501

Forward-Looking Statements

This press release contains “forward-looking information” as defined under applicable Canadian securities law (“forward-looking statements”) which reflect management’s expectations regarding objectives, plans, goals, strategies, future growth, results of operations, performance, business prospects and opportunities of the REIT, including, but not limited to, statements concerning anticipated management fees, leasing and incentive fees the REIT expects to receive from the Joint Venture, certain tax implication to the REIT and its unitholders that may result from the contribution of the Portfolio to the Joint Venture, including the potential for special distributions, and the amount and intended use of liquidity generated by the contribution of the Portfolio to the Joint Venture. The words “plans”, “expects”, “scheduled”, “estimates”, “intends”, “anticipates”, “projects”, “believes” or variations of such words and phrases (including negative variations) or statements to the effect that certain actions, events or results “may”, “will”, “could”, “would”, “might”, “occur”, “be achieved” or “continue” and similar expressions identify forward-looking statements. Certain statements included in this press release may be considered a “financial outlook” for purposes of applicable Canadian securities laws, and as such, the financial outlook may not be appropriate for purposes other than to understand management’s current expectations and plans relating to the future, as disclosed in this press release. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable by management of the REIT as of the date of this press release, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Such estimates, beliefs and assumptions include, but are not limited to, results of operations and the REIT’s income for tax purposes for the current taxation year (including income to be realized as a consequence of the contribution of the Portfolio to the Joint Venture), future prospects and opportunities, the demographic and industry trends remaining unchanged, future growth opportunities for the REIT and its properties, no change in legislative or regulatory matters, future levels of indebtedness, the amount of ordinary cash distributions to be paid by the REIT in the current year remaining unchanged, the tax laws as currently in effect remaining unchanged, the continual availability of capital, the current economic conditions remaining unchanged, continued positive net absorption and declining vacancy rates in the markets in which the REIT’s properties are located, and the scope and duration of the COVID-19 pandemic and its impact on the REIT.

When relying on forward-looking statements to make decisions, the REIT cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not the times at or by which such performance or results will be achieved, if achieved at all. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements, including, but not limited to, the factors discussed or referenced under “Risk Factors” in the REIT’s most recently filed annual information form and management’s discussion and analysis, each of which are available under the REIT’s profile on SEDAR at www.sedar.com. These forward-looking statements have been approved by management to be made as of the date of this press release and, except as expressly required by applicable law, the REIT assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

The COVID-19 pandemic has cast additional uncertainty on the REIT’s prior expectations, future outlook, anticipated events and projections. There can be no assurance that they will continue to be valid. Given the rapid pace of change with respect to the impact of the COVID-19 pandemic, it is premature to make further assumptions about these matters. The duration, extent and severity of the impact the COVID-19 pandemic, including measures to prevent its spread, will have on the REIT’s business is highly uncertain and impossible to accurately predict at this time.

·       Automation solution increases processing capacity to 6,000 PCR tests per day, expandable to 12,000 daily tests with minor upgrades

·       Client entered into contract with the State of Kentucky to provide PCR testing for nursing home facilities

NEW YORK, NY, and REHOVAT, ISRAEL, March 29, 2021 (GLOBE NEWSWIRE) —

via NewMediaWire —Todos Medical, Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as developing blood tests for early detection of cancer and Alzheimer’s disease, today announced the successful installation of automated lab equipment and completion of training for a lab client in Brooklyn, NY. The implementation of the Todos automation solution has expanded the lab’s processing capacity to 6,000 PCR tests per day from 500 PCR tests per day, with the potential to quickly expand to up to 12,000 PCR tests per day. The lab will be implementing EUA approved PCR testing for COVID-19 testing, as well as COVID + influenza A & B PCR testing upon request for select clients. Additionally, through the future implementation of pooling, the lab could potentially increase processing capacity to in excess of 40,000 PCR tests per day at a 4:1 ratio.

The Todos automation solution is expected to be instrumental in helping this lab client service a new contract recently entered into with the State of Kentucky to conduct testing for nursing home clients. The Company expects nursing homes to continue to conduct surveillance testing for COVID-19 for at least the next several years.

“After considerable work helping to complete the installation process, our Brooklyn lab client has successfully completed training and is now able to report PCR testing results utilizing our process,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We are now focused on continuing to serve our lab clients, with a hyper-focus on helping them upgrade their saliva PCR testing capabilities to meet the needs of new testing populations that we expect will be conducting COVID testing for the foreseeable future, such as schools, skilled nursing facilities and sports & entertainment venues.”

For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com     

For testing and PPE inquiries, please email [email protected].

About Todos Medical Ltd.

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF), engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed a strategic partnership with Integrated Health LLC to deploy mobile COVID-19 testing in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target the reproductive mechanism of coronaviruses.

For more information, please visit https://www.todosmedical.com/.

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Investor Contact:

Richard Galterio

Ascendant Partners LLC

Managing Partner

732-642-7770

[email protected]

Todos Corporate Contact:

Priyanka Misra

Todos Medical

(917) 983-4229 ext. 103

[email protected]

PHILADELPHIA, March 29, 2021 (GLOBE NEWSWIRE) — The Business Intelligence Group today announced that Ambiq was named a winner in its Artificial Intelligence Excellence Awards program. Ambiq is an industry-recognized technology leader in ultra-low power processor solutions for enabling intelligence at the IoT endpoints.

The Apollo4 SoC, the 4^th generation system processor solution built on Ambiq’s proprietary Subthreshold Power-Optimized Technology (SPOT™) platform, is designed to enable the battery-powered IoT endpoint devices of tomorrow to achieve a higher level of intelligence without sacrificing battery life.

“For the last ten years, Ambiq has consistently delivered record-low-power processor solutions for IoT,” said Fumihide Esaka, Chairman and CEO of Ambiq. “We are proud that our Apollo4 SoC is honored for its ability to enable intelligence for battery-powered endpoint devices with its performance and energy efficiency.”

“We are so proud to name Ambiq as a winner in our inaugural Artificial Intelligence Excellence Awards program,” said Maria Jimenez, chief nominations officer for Business Intelligence Group. “It was clear to our judges that Ambiq was using AI to improve the lives of their customers and employees. Congratulations to the entire team!”

About Ambiq

Ambiq was founded in 2010 with the mission to foster a cleaner, greener, and safer environment where mobile and portable devices could either reduce or eliminate their total power consumption from the batteries. Ambiq has been laser-focused on inventing and delivering the most revolutionary microcontroller (MCU) and System-on-Chip (SoC) solutions in the market for the last ten years. Through the advanced Subthreshold Power Optimized Technology (SPOT™) platform, Ambiq has helped many leading manufacturers worldwide create products that can operate for days, months, and sometimes years with a lithium battery or a single charge. For more information, please visit www.ambiq.com.

About Business Intelligence Group www.bintelligence.com
The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, these programs are judged by business executives having experience and knowledge. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

Contact

Charlene Wan
+1.512.879.2850
[email protected]

Maria Jimenez
+1 909-529-2737
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a907fc81-1e89-4633-81ba-85737c649a64

SALT LAKE CITY, March 29, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer. In this role, he will be responsible for accelerating growth initiatives and building commercial capabilities, and digital platforms to better serve patients and healthcare providers, while driving increased market demand for the company’s portfolio of existing and new products and services.

Santa, who reports directly to Paul J. Diaz, president and CEO of Myriad Genetics, brings proven healthcare expertise spanning consumer and digital businesses, as well as commercial transformation, portfolio management, and new growth channels. He previously served as Chief Revenue Officer of Rally Health, Inc., a division of Optum within UnitedHealth Group, where he spearheaded consumer digital health strategies and online mobile solutions that make it easier for consumers to take charge of their health. He led key Rally business functions, including sales for payer, provider, and employer markets. He also was responsible for client management and partner relationships while opening new markets, optimizing business lines, and expanding into growing areas such as telehealth.

At Myriad, Santa will lead strategic initiatives that advance the company’s growth plans, expand its reach, and drive customer-centric commercial capabilities across sales, marketing, and digital platforms. He will lead key enabling functions including enterprise marketing, digital, brand and marketing communications. In addition, he will lead the company’s efforts to use its deep reservoir of patient data to further enhance its genetic insights and expand the company’s commercial reach.

As part of Santa’s team, Jeff Borcherding has been promoted to senior vice president and Chief Marketing Officer, responsible for the company’s integrated product marketing initiatives designed to increase test volumes and revenue. Borcherding previously was general manager for GeneSight^®, leading sales, marketing, customer services, and medical affairs.

Strengthening Diversity, Equity and Inclusion

Myriad announced that Gwendolyn F. Turner is joining the company to lead diversity, equity and inclusion (DEI) initiatives and support the company’s broader commitment to addressing environmental, social and governance matters (“ESG”). Turner previously served as head of equity, inclusion, diversity and talent engagement at Northwest Permanente/Kaiser Permanente. She will report to Jayne Hart, Chief People Officer.

In her new position, Turner will be responsible for further strengthening Myriad Genetics’ commitment to diversity, equity and inclusion, applying her leadership and functional experience to support socially inclusive product development, talent development, and related internal and external practices. As part of her responsibilities, Turner will drive company-wide programs that promote a strong inclusive culture. She also will oversee Myriad’s Women’s Leadership Group and DEI Forum, comprised of hundreds of employees from a range of backgrounds, businesses and functions.

“The addition of highly experienced, proven leaders from other innovative companies and organizations across the healthcare ecosystem is a significant component of our transformation and growth plan.  At the same time, we are coupling new external perspectives with high-performing talent from within Myriad so we can leverage a full range of experiences and perspectives,” said Diaz. “We are fortunate to have a senior executive of Eric’s caliber joining us to spearhead new growth initiatives together with proven marketing leaders like Jeff.  As part of our ongoing commitment to teammate engagement, ESG and diversity, equity and inclusion, we will benefit from Gwen’s deep experience as a global human resources and diversity leader who will significantly advance our efforts in an area that is at the heart of our purpose of improving health and wellbeing for all.”

About Myriad Genetics

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where genetic testing can significantly improve patient care and lower healthcare costs. For more information on how Myriad fulfills its purpose, please visit the Company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to accelerating growth initiatives, building commercial capabilities and digital platforms to better serve patients and healthcare providers, and driving increased market demand for the company’s portfolio of existing and new products and services; increasing test volumes and revenue; promoting a strong inclusive culture; and the Company’s strategic directives under the caption “About Myriad Genetics.”  These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements.  These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.  All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.